The9's investee Nanyang Biologics moves closer to a Nasdaq listing after shareholders approve the RFAI transaction
Executive summary: Nanyang Biologics secured shareholder approval for the RFAI restructuring at an extraordinary general meeting, a prerequisite for its planned Nasdaq IPO. The approval advances a high‑profile Chinese AI‑biotech toward a U.S. listing, giving The9 a sizable equity stake and providing a test case for cross‑border biotech capital markets.
Who is involved: The9 Limited (Nasdaq: NCTY), Nanyang Biologics (NYB), RFAI restructuring vehicle, shareholders of NYB, and the U.S. SEC.
Likely next: NYB will file its Form 20‑F with the SEC, undergo a roadshow, and target a Nasdaq debut in the first half of 2027, while The9 monitors its 15‑16% post‑IPO ownership.
The shareholder approval of the RFAI transaction by Nanyang Biologics removes a pivotal internal barrier to its planned Nasdaq listing, moving the company from a private restructuring phase toward the public market regimen. With the vote cleared, NYB can now proceed to file the necessary registration statements with the SEC, a step that will determine whether the offering can proceed on the timetable set by management. The9 Limited’s disclosed intention to retain roughly 15‑16% of the combined entity after the transaction suggests that the Chinese internet‑gaming group intends to maintain a meaningful, though minority, stake in the biotech venture, preserving its strategic exposure to AI‑driven drug discovery without assuming control. From a market perspective, a successful Nasdaq debut would provide NYB with access to a deeper pool of capital and enhanced visibility among global biotech investors, potentially accelerating its research and development pipeline. For The9, the retained stake offers a way to benefit from any upside in NYB’s valuation while limiting direct exposure to the volatile biotech sector. However, the ultimate realization of these benefits remains contingent on SEC clearance and prevailing investor sentiment toward life‑science listings, meaning that any near‑term outlook must be tempered by the acknowledgment that the listing is not yet assured.
What's next — scenarios
Successful Nasdaq Debut (55%)
Increased liquidity and R&D capital for NYB, with The9 realizing potential valuation uplift on its 15-16% stake.
- SEC approval of Form F-1
- Successful pricing of IPO shares
Regulatory/Market Delay (30%)
Capital constraints for NYB's drug discovery pipeline and extended period of non-liquidity for The9's investment.
- SEC request for additional disclosures
- Weak sentiment in US biotech IPO market
Failed Listing/Restructuring Pivot (15%)
NYB remains private; The9 must reassess the strategic value of its non-controlling stake without a public exit path.
- Inability to meet Nasdaq listing requirements
- Failure of follow-on capital raise
What to watch
- SEC filing of NYB registration statement (next 60 days)
- Nasdaq biotech sector index volatility (next 30 days)
- Nanyang Biologics investor updates on R&D funding status (next 90 days)
Timeline
- — The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting (PR Newswire)
Analysis — what this means
Likely next events
- NYB files Form 20‑F with the SEC by Q4 2026.
- Roadshow and pricing expected in H1 2027.
- The9 discloses post‑IPO stake (15‑16%) in its next quarterly filing.
Sectors affected
- AI‑driven drug discovery
- Biotech IPOs
- Nasdaq listings of Chinese companies
Regulatory implications
- SEC scrutiny of foreign biotech financials and corporate governance.
- Compliance with RFAI restructuring rules and U.S. securities law.
Historical parallels
- Zai Lab (2021) and BeiGene (2020) Nasdaq listings of Chinese biotechs.
- Recent wave of Chinese AI‑healthcare firms seeking U.S. listings (2023‑2025).